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Abstract
Purpose The purpose of our study was to determine the value
of 18F-FDG PET before and after induction chemotherapy in
patients with oesophageal adenocarcinoma for the early pre-
diction of a poor pathologic response to subsequent preoper-
ative chemoradiotherapy (CRT).
Methods In 70 consecutive patients receiving a three-step
treatment strategy of induction chemotherapy and preopera-
tive chemoradiotherapy for oesophageal adenocarcinoma,
18F-FDG PET scans were performed before and after induc-
tion chemotherapy (before preoperative CRT). SUVmax,
SUVmean, metabolic tumour volume (MTV), and total lesion
glycolysis (TLG) were determined at these two time points.
The predictive potential of (the change in) these parameters
for a poor pathologic response, progression-free survival
(PFS) and overall survival (OS) was assessed.
Results A poor pathologic response after induction chemo-
therapy and preoperative CRT was found in 27 patients
(39 %). Patients with a poor pathologic response experienced
less of a reduction in TLG after induction chemotherapy
(p < 0.01). The change in TLG was predictive for a poor path-
ologic response at a threshold of −26 % (sensitivity 67 %,
specificity 84 %, accuracy 77 %, PPV 72 %, NPV 80 %),
yielding an area-under-the-curve of 0.74 in ROC analysis.
Also, patients with a decrease in TLG lower than 26 % had
a significantly worse PFS (p = 0.02), but not OS (p = 0.18).
Conclusions 18F-FDG PET appears useful to predict a poor
pathologic response as well as PFS early after induction che-
motherapy in patients with oesophageal adenocarcinoma un-
dergoing a three-step treatment strategy. As such, the early
18F-FDG PET response after induction chemotherapy could
aid in individualizing treatment bymodification or withdrawal
of subsequent preoperative CRT in poor responders.
Keywords 18F-FDGPET .Treatment response .Oesophageal
cancer . Chemotherapy . Chemoradiotherapy
Introduction
The long-term survival of patients with locoregionally ad-
vanced oesophageal cancer remains quite poor despite
considerable advances in surgery, radiotherapy, and
chemotherapy, with 5-year survival rates still below
50 % [1, 2]. Multimodality treatment strategies have been
implemented in an effort to improve the outcome
achieved with surgery alone [3]. Since early studies
showed that adjuvant therapy did not improve outcomes
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[4–7], contemporary research mainly focused on neoadju-
vant strategies, which resulted in improved resection
rates, pathologic downstaging, and a reduction in disease
recurrences [3]. As a result, preoperative concurrent che-
moradiotherapy (CRT) followed by oesophagectomy is
commonly applied in clinical practice [8].
An important observation in patients treated with
trimodality therapy (i.e., preoperative CRT followed by
oesophagectomy) is that the most common pattern of
treatment failure is now distant progression [8, 9]. In an
attempt to eliminate micrometastases and thereby improve
the distant failure rate and overall outcome, additional
induction chemotherapy before trimodality therapy has
been investigated in the United States and Europe, as well
as in Asia [10–29]. Results of comparative studies have
been inconclusive with some studies reporting a benefit of
induction chemotherapy [15, 16], while others were
equivocal [27, 29]. Nonetheless, induction chemotherapy
is thought to have a number of potential advantages in-
cluding improvement of swallowing/nutritional status and
obviating the need for feeding tubes in patients presenting
with dysphagia [11, 12, 14, 18, 19, 22, 24]. More impor-
tantly, it has been suggested that the use of induction
chemotherapy may permit early identification of poorly
responding patients in whom neoadjuvant treatment is in-
effective or even harmful [24, 30–32].
18F-fluorodeoxyglucose positron emission tomography
(18F-FDG PET) is a well-established imaging modality for
initial staging and re-staging after preoperative CRT for the
detection of distant (interval) metastases [33–37]. 18F-FDG
PET has been shown to bemore accurate than other modalities
in predicting pathologic response to neoadjuvant chemother-
apy or CRT for oesophageal cancer [38, 39]. However, current
evidence is limited with regard to the value of 18F-FDG PET
for response prediction in the setting of a three-step strategy of
induction chemotherapy and preoperative CRT followed by
oesophagectomy. Therefore, the aim of this study was to de-
termine the value of 18F-FDG PET scanning at baseline and
after induction chemotherapy for the early prediction of a poor
versus good pathologic response (i.e. >10 % versus ≤10 %
residual carcinoma) to subsequent preoperative CRT.
Material and methods
This retrospective study has been approved by our Institutional
Review Board, and the need for written informed consent was
waived. The study was conducted in accordance with the
Health Insurance Portability and Accountability Act (HIPAA)
and the checklist from the STAndards for the Reporting of
Diagnostic accuracy studies (STARD) statement (http://www.
stard-statement.org) [40].
Study population
From a prospectively acquired database, we extracted all con-
secutive patients with a biopsy-proven potentially resectable
adenocarcinoma of the oesophagus or gastro-oesophageal
junction and no distant metastases that underwent a three-
step treatment strategy of induction chemotherapy and preop-
erative chemoradiotherapy followed by surgery at our institu-
tion fromMarch 2006 to February 2013. Patients were exclud-
ed if one of two 18F-FDG PET scans of interest were either
not available or acquired at another institution. Also, non-
FDG-avid tumours at baseline, Siewert type 3 gastro-
oesophageal junction tumours, and patients with a stent in-
situ at the time of scanning were excluded. Finally, patients
with a time interval between completion of preoperative che-
moradiation and surgery of less than 5 weeks or more than
14 weeks - indicating urgent and salvage resections, respec-
tively - were excluded.
Treatment regimen
All patients were treated by induction chemotherapy and sub-
sequent external beam radiation with concurrent chemothera-
py. The backbone of induction chemotherapy generally
consisted of a fluoropyrimidine (intravenous 5-FU or oral
capecitabine) and oxaliplatin, with the addition of either
leucovorin (54 % of cases) or docetaxel (37 % of cases) [17,
27]. Other (sporadic) induction chemotherapy regimens in-
cluded carboplatin/paclitaxel (3 %), cisplatin/paclitaxel
(1.5 %), cisplatin/irinotecan (1.5 %), 5-FU monotherapy
(1.5 %) and capecitabine/oxaliplatin/epirubicin (1.5 %).
Radiation therapy consisted of a total radiation dose of
45.0 Gy (4 %) or 50.4 Gy (96 %) delivered in daily fractions
of 1.8 Gy using intensity modulated radiation therapy (IMRT;
69 %) or proton therapy (31 %). The chemotherapy concur-
rently administered with radiation generally consisted of a
fluoropyrimidine (intravenous or oral) with either a platinum
compound (69 %) or docetaxel (17 %). Other (sporadic) con-
current chemotherapy regimens included carboplatin/
paclitaxel (3 %), 5-FU/paclitaxel (3 %), 5-FU/oxaliplatin/do-
cetaxel (3 %), oxaliplatin/docetaxel/irinotecan (3 %),
oxaliplatin/docetaxel (1 %), and cisplatin/irinotecan (1 %).
After completion of chemoradiation, either a transthoracic
(Ivor-Lewis), transhiatal, total (three-field technique), or min-
imally invasive oesophagectomy was performed with curative
intent at the discretion of the treating surgeon.
Histopathologic assessment
Histopathologic examination of the resected specimen was
standardized in accordance with the seventh edition of the
American Joint Committee on Cancer protocol for TNM-
classification [41]. The degree of pathologic response to
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neoadjuvant treatment was graded as follows [42]: complete
absence of residual cancer (tumour regression grade [TRG] 1),
1-10 % residual carcinoma (TRG 2), 11-50 % residual carci-
noma (TRG 3), and >50 % residual carcinoma (TRG 4). A
poor pathologic response (defined as TRG 3–4) as opposed to
a good pathologic response (defined as TRG 1–2) was con-
sidered the reference standard of this study.
Image acquisition
18F-FDG PET/computed tomography (CT) scans were per-
formed on an integrated PET/CT system (Discovery RX, ST,
or STE; GE Medical Systems, Milwaukee [WI], USA).
Before 18F-FDG PET, a CT scan was acquired (120 kV peaks,
300 mA, 0.5 seconds rotation, pitch of 1.375, slice thickness
3.75 mm, and slice interval 3.27 mm) for attenuation correc-
tion purposes. 18F-FDG PET scans were acquired 60–90
minutes after administration of 18F FDG with a dose of
555–740 MBq, in either two-dimensional (2-D) or three-
dimensional (3-D) acquisition mode at 3–5 minutes per bed
position. Images were reconstructed using ordered-subset ex-
pectation maximization in 2-D or iterative reconstruction in
3-D images. All analyses were performed on the attenuation-
corrected images.
Image analysis
The primary tumour was defined as the volume of interest
(VOI) and delineated on the 18F-FDG PET scans using a
semi-automatic gradient-based delineation method from com-
mercially available software (MIM Software, Cleveland
[OH], USA). This contouring method has recently been vali-
dated in a multi-observer study that showed superiority over
manual and threshold methods [43]. The following quantita-
tive features were extracted from the VOIs of the 18F-FDG
PET scans at baseline and after induction chemotherapy (be-
fore preoperative CRT): maximum and mean standardized
uptake value (SUVmax and SUVmean), metabolic tumour vol-
ume (MTV) and total lesion glycolysis (TLG). The MTV was
automatically calculated by the software by summing up the
areas within each two-dimensional transverse tumour contour
multiplied by the corresponding slice thickness. The TLGwas
calculated by multiplyingMTV by SUVmean [44]. In addition,
the relative changes (in %) of these parameters between 18F-
FDG PET at baseline and 18F-FDG PET after induction che-
motherapy were calculated and included in the analysis.
Statistical analysis
First, the association between clinical parameters and poor
versus good pathologic response was studied using the chi-
square test (or Fisher’s exact test in case of small cell count)
for categorical parameters, and Student’s T-test for parametric
continuous parameters. The association between the quantita-
tive 18F-FDG PET parameters and pathologic response was
quantified using logistic regression analysis providing odds
ratios (ORs) with 95 % confidence intervals (CIs). Multiple
18F-FDG PET parameters were logarithmically transformed to
meet the assumption of linearity on the logit scale. For these
parameters, the relative changes (%) were calculated using the
logarithmically transformed parameter values before and after
induction chemotherapy.
Second, receiver operating characteristics (ROC) curve
analyses (providing area-under-the-curve [AUC] values) were
used to assess the potential of the studied 18F-FDG PET pa-
rameters to discriminate poor responders from good re-
sponders. For the 18F-FDG PET parameter with the highest
discriminatory ability (AUC), the sensitivity, specificity, accu-
racy, positive predictive value (PPV), and negative predictive
value (NPV) were calculated for an optimal threshold that was
determined by giving equal weight to sensitivity and specific-
ity on the ROC curve.
Third, the Kaplan-Meier method was applied to estimate
progression-free and overall survival differences among pa-
tients predicted to have a poor versus good response based on
the 18F-FDG PET parameter with the highest discriminatory
ability. For the survival analysis, the log-rank test was used to
determine significance. Progression-free survival and overall
survival were calculated from the starting date of induction
chemotherapy to the date of disease progression after surgery
or the date of death, respectively. In patients who were free of
disease progression or alive at last follow-up, the date of last
follow-up was used to censor progression-free or overall sur-
vival times, respectively. Statistical analysis was performed
using SPSS 23.0 (IBM Corp., Armonk [NY], USA) and R
3.1.2 open-source software (http://www.R-project.org). A p-
value <0.05 was considered statistically significant.
Results
From a total of 132 patients with an oesophageal adenocarci-
noma who underwent induction chemotherapy and preopera-
tive chemoradiotherapy followed by surgery in the study pe-
riod, 70 were considered eligible for analysis. Some excluded
patients missed at least one of two 18F-FDG PET scans of
interest performed at our institution (n = 28); these patients
had similar response and survival rates compared to the in-
cluded cohort. Other excluded patients had a Siewert type 3
gastro-oesophageal junction tumour (n = 15), a non-FDG avid
tumour (n = 6), a stent in-situ at the time of scanning (n = 1), or
underwent an urgent or salvage oesophagectomy (n = 1 and
n = 11, respectively).
Among the 70 eligible patients, 27 (39 %) had a poor path-
ologic response (TRG 3–4) to neoadjuvant treatment, whereas
43 (61 %) had a good pathologic response (TRG 1–2).
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Patients with a poor response had a mean age of 60 years and
96% (n = 26) of themwere male, whereas patients with a good
response had a mean age of 59 years and 88 % (n = 38) of
them were male. None of the studied baseline characteristics
were significantly related to the pathologic response to neoad-
juvant treatment (Table 1). More specifically, only small
non-significant differences regarding pathologic response for
the various induction chemotherapy regimens, radiation thera-
py characteristics and concurrent chemotherapy regimens
were found. However, worse tumour characteristics (i.e.,
higher clinical T-stage, signet ring cell adenocarcinoma, poor
differentiation grade) and co-morbidities (i.e., cardiac co-
Table 1 Patient and treatment-
related characteristics Characteristic Poor response (n = 27) Good response (n = 43) p value
Male gender 26 (96.3) 38 (88.4) 0.39
Age (years)† 59.9 ± 11.5 59.4 ± 10.6 0.86
BMI (kg/m2)† 30.3 ± 5.0 30.0 ± 5.0 0.79
Cardiac co-morbidity 7 (25.9) 7 (16.3) 0.33
Diabetes mellitus 7 (25.9) 8 (18.6) 0.47
COPD 3 (11.1) 1 ( 2.3) 0.29
Smoking at diagnosis 8 (29.6) 8 (18.6) 0.29
Karnofsky performance status† 85.6 ± 6.4 85.6 ± 6.3 0.99
Tumor location 0.70
Distal third of esophagus 25 (92.6) 38 (88.4)
Gastro-esophageal junction 2 ( 7.4) 5 (11.6)
EUS-based tumor length (cm)† 6.3 ± 2.8 6.1 ± 2.9 0.87
Histologic differentiation grade 0.35
Moderate 12 (44.4) 24 (55.8)
Poor 15 (55.6) 19 (44.2)
Signet ring cell adenocarcinoma 6 (22.2) 4 ( 9.3) 0.17
Clinical T-stage 0.14
cT2 1 ( 3.7) 7 (16.3)
cT3 26 (96.3) 36 (83.7)
Clinical N-stage 0.73
cN0 7 (26.9) 10 (23.3)
cN+ 19 (73.1) 33 (76.7)
Missing 1 -
Induction chemotherapy regimen 0.81
Fluoropyrimidine/oxaliplatin/leucovorin 14 (51.9) 24 (55.8)
Fluoropyrimidine/oxaliplatin/docetaxel 10 (37.0) 16 (37.2)
Other 3 (11.1) 3 ( 7.0)
Radiation treatment modality 0.79
IMRT 18 (66.7) 30 (69.8)
Proton therapy 9 (33.3) 13 (30.2)
Total radiation dose 1.00
45.0 Gy 1 ( 3.7) 2 ( 4.7)
50.4 Gy 26 (96.3) 41 (95.3)
Concurrent chemotherapy regimen 0.25
Fluoropyrimidine/platinum 18 (66.7) 30 (69.8)
Fluoropyrimidine/docetaxel 3 (11.1) 9 (20.9)
Other 6 (22.2) 4 ( 9.3)
Data are presented as numbers with percentages in parentheses
† : Expressed as mean ± SD.
COPD: Chronic obstructive pulmonary disease. EUS: Endoscopic ultrasound. IMRT: Intensity-modulated
radiotherapy
74 Eur J Nucl Med Mol Imaging (2017) 44:71–80
morbidity, diabetes mellitus, chronic obstructive pulmonary
disease, and smoking at diagnosis) were consistently observed
more frequently in the poor response group.
Baseline 18F-FDG PET parameters, SUVmax, and SUVmean
after induction chemotherapy were not related to pathologic
poor versus good response (Table 2). However, both a larger
MTV and a larger TLG after induction chemotherapy were
significantly related to a higher chance of a poor pathologic
response (p = 0.01). The relative changes after induction
chemotherapy in 18F-FDG PET intensity parameters (i.e.,
ΔSUVmax and ΔSUVmean) and metabolic tumour volume
(i.e., ΔMTV) were also significantly related to pathologic re-
sponse (p = 0.01), and their discriminatory ability appeared to
be superior compared with single time point measurements
(AUC range 0.71-0.72 vs. 0.52-0.69; Table 2). The associa-
tion of the relative change in (the logarithmically transformed)
total lesion glycolysis (ΔTLG) with pathologic response was
highly significant (p < 0.01) and this parameter yielded the
highest discriminatory ability (AUC 0.74).
The ideal cut-off value for ΔTLG to distinguish poor
pathologic responders from good responders was statisti-
cally determined at −26 % (i.e., a 26 % decrease). Patients
with a ΔTLG above (n = 25) versus below (n = 45) this
threshold had a poor pathologic response in 72 % versus
20 % of cases, respectively. At the threshold of −26 %,
the ΔTLG yielded a sensitivity of 67 % (95 % CI: 51-
79 %), specificity of 84 % (95 % CI: 74-91 %), accuracy
of 77 % (95 % CI: 65-86 %), PPV of 72 % (95 % CI: 55-
85 %), and NPV of 80 % (95 % CI: 71-87 %) for
predicting a poor pathologic response (Fig. 1). Of note,
the threshold for the relative change in the logarithmically
transformed TLG values of −26 % compared best to a
threshold for the relative change in the originally scaled
TLG values of −74 %. However, this originally scaled
ΔTLG yielded a slightly lower predictive performance
(AUC 0.71, with sensitivity 70 % [95 % CI: 54-83 %],
specificity 74 % [95 % CI: 64-83 %], accuracy 73 %
[95 % CI: 60-83 %], PPV 63 % [95 % CI: 49-75 %],
and NPV 80 % [95 % CI: 69-89 %]).
Post-operative 30-day and 90-day mortality rates were
1 % (1 of 70) and 4 % (3 of 70), respectively. These three
patients (who were part of the predicted good responders
group) were excluded from survival analysis. For patients
alive at last follow-up, the median follow-up duration was
48 months (range 15 to 99). In the 25 patients with a
predicted poor response based on (the logarithmically
transformed) ΔTLG the median progression-free survival
was 17 months, whereas the median progression-free sur-
vival in the 42 patients with a predicted good response
was not reached (Fig. 2a). The progression-free survival
was significantly better for the predicted good responders
compared to the predicted poor responders based on
ΔTLG (p = 0.02). Although overall survival rates ap-
peared higher in patients with a predicted good response
Table 2 Logistic regression and
ROC curve analysis of 18F-FDG




Parameter Poor response (n = 27)
Median [IQR]
Good response (n = 43)
Median [IQR]
OR 95 % CI p value AUC
18F-FDG PET before induction chemotherapy
SUVmax
† 14.2 [ 8.2, 18.6] 14.7 [ 9.7, 20.4] 0.90 0.39 – 2.06 0.80 0.52
SUVmean
† 6.5 [ 4.7, 9.4] 6.4 [ 4.9, 8.9] 0.76 0.28 – 2.08 0.60 0.53
MTV (mL)† 24.2 [ 14.9, 46.8] 26.4 [ 14.4, 45.1] 0.96 0.53 – 1.73 0.90 0.52
TLG† 171 [ 88.9, 299] 203 [ 61.1, 454] 0.93 0.61 – 1.43 0.75 0.52
18F-FDG PET after induction chemotherapy
SUVmax
† 7.0 [ 5.2, 9.2] 5.0 [ 3.3, 7.8] 2.51 0.96 – 6.59 0.06 0.66
SUVmean
† 4.3 [ 3.5, 5.2] 3.7 [ 2.6, 4.9] 2.44 0.68 – 8.77 0.17 0.62
MTV (mL)† 13.1 [ 7.4, 18.6] 7.0 [ 2.5, 12.0] 2.60 1.32 – 5.11 0.01* 0.69
TLG† 48.9 [ 28.4, 81.0] 24.5 [ 8.6, 64.7] 1.90 1.16 – 3.10 0.01* 0.68
Relative difference
ΔSUVmax (%) −20.5 [−32.0,-12.5] −32.4 [−48.8,-24.7] 1.05 1.01 – 1.09 0.01* 0.71
ΔSUVmean (%) −21.3 [−32.9,-21.3] −31.4 [−45.5,-19.7] 1.04 1.01 – 1.07 0.01* 0.71
ΔMTV (%) −13.2 [−37.2, −7.9] −39.1 [−63.8,-26.1] 1.04 1.01 – 1.06 0.01* 0.72
ΔTLG (%) −19.5 [−34.1, −9.8] −34.0 [−52.7,-29.9] 1.05 1.02 – 1.09 <0.01* 0.74
† : Logarithmically transformed for logistic regression analysis to meet the assumption of linearity on the logit
scale.
*: Significantly associated with poor versus good pathologic response (p < 0.05).
AUC: Area under the (receiver operating characteristic [ROC]) curve. IQR: Interquartile range. MTV: Metabolic
tumor volume. SUV: Standardized uptake value. TLG: Total lesion glycolysis.
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(median, not reached) compared to predicted poor re-
sponders (median, 70 months), this difference was not
statistically significant (p = 0.18; Fig. 2b).
Discussion
In this study, the value of 18F-FDG PET before and after
induction chemotherapy for the prediction of response to
neoadjuvant treatment was investigated in patients under-
going induction chemotherapy followed by trimodality
therapy for oesophageal adenocarcinoma. Significant asso-
ciations were found between treatment-induced changes in
studied 18F-FDG PET parameters and histopathologic tu-
mour regression defined as poor response (TRG 3–4) ver-
sus good response (TRG 1–2).
A decrease of less than 26 % in (the logarithmically
transformed) TLG after induction chemotherapy, indicating
only a mild reduction in intensity and volume of FDG-
uptake of the primary tumour, predicted a poor pathologic
response with a specificity of 84 % and PPV of 72 %.
This implies that the baseline (a priori) chance of a poor
pathologic response of 39 % (i.e., the overall prevalence)
almost doubled to 72 % (i.e., the PPV) in predicted poor
responders. This is particularly interesting when consider-
ing modification of the chemotherapy regimen adminis-
tered concurrently with preoperative CRT after induction
chemotherapy (e.g., in patients with burdening toxicity
from induction chemotherapy) or even omission of inef-
fective and toxic preoperative CRT in predicted poor re-
sponders. On the other hand, a strong reduction of more
than 26 % in TLG after induction chemotherapy predicted
a good pathologic response with a sensitivity of 67 % and
NPV of 80 %. This implies that the baseline (a priori)
chance of a good pathologic response of 61 % (i.e., the
overall prevalence) increased to 80 % (i.e., the NPV) in
predicted good responders. This indicates that 18F-FDG
PET before and after induction chemotherapy provides a
reasonable basis to encourage good responders to have
induction chemotherapy and to proceed with preoperative
chemoradiotherapy.
Several single-arm phase I-II studies [10–14, 19, 21–23,
25] and two retrospective comparative studies [15, 16]
found promising results with the three-step treatment strat-
egy compared to preoperative CRT without induction che-
motherapy in terms of treatment response, R0 resection
rates, and survival rates. However, this potential superior-
ity was not found in a retrospective comparative study
[17] and two prospective randomized phase II studies
[27, 29]. One study suggested that only patients with stage
III and IVa (and not stage II) disease who received
induction chemotherapy had a significant survival advan-
tage over preoperative CRT alone [16]. The three-step ap-
proach has not been evaluated in the context of a phase
III trial. Therefore, the use of induction chemotherapy to
improve oncologic outcomes remains a subject of debate.
Nonetheless, the response to induction chemotherapy may
serve as a marker for tumour sensitivity indicating whether
benefit is to be expected from subsequent CRT or whether
different chemotherapeutic agents should be incorporated
into the preoperative CRT [24–26].
Since oesophageal cancer patients with a poor patholog-
ic response to neoadjuvant treatment do not seem to ben-
efit from this treatment but are exposed to its treatment-
related toxicity [11, 13, 30, 31], accurately predicting path-
ologic response before or early during treatment would
produce much-needed knowledge to help individualize
therapy. In this regard, the predictive value of 18F-FDG
PET response has previously been reported in preoperative
chemotherapy studies of patients with oesophageal
Fig. 1 Scatter plot demonstrating the percentage of change in the
logarithmically transformed total lesion glycolysis (ΔTLG) after
induction chemotherapy before preoperative chemoradiotherapy for
oesophageal cancer in 27 poor versus 43 good pathologic responders.
Horizontal continuous lines represent group means and the dotted line
represents the optimal discriminatory cut-off level for ΔTLG of −26 %
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adenocarcinoma [45, 46]. In the subsequent MUNICON
trial from that group [32], 18F-FDG PET-based poor re-
sponders early during preoperative chemotherapy were re-
ferred for immediate surgery rather than continuation of
preoperative chemotherapy, and this discontinuation of in-
effective chemotherapy did not adversely affect outcome
compared with continuing such therapy [32].
The current study demonstrates that 18F-FDG PET be-
fore and after induction chemotherapy yields a moderate
ability to predict a poor pathologic response to subsequent
preoperative CRT. The value of 18F-FDG PET in this set-
ting has been previously described in four smaller cohorts
[20, 24, 26, 47], one of which had no histopathologic ref-
erence as no surgery was performed [26]. Similar to the
current study, three previous studies with 45, 55, and 46
patients, respectively [20, 24, 47], performed 18F-FDG PET
before and after induction chemotherapy and reported a
significant association between early 18F-FDG PET re-
sponse and histopathologic tumour regression. Two studies
reported the predictive performance of 18F-FDG PET for
predicting a poor pathologic response with sensitivities of
52 % and 68 %, and specificities of 60 % and 52 % [20,
47]. The differences with the current study (sensitivity
67 %, specificity 84 %) may be explained by varying
18F-FDG PET hardware, scan protocols, and reconstruction
algorithms between studies [20, 47] and within one multi-
center study [47], by the different applied thresholds for
18F-FDG PET response [20, 47], and by the different
treatment regimens used in other studies [20, 47]. One pre-
vious study only reported on the value of 18F-FDG PET
before and after induction chemotherapy to predict residual
cancer as opposed to a pathologic complete response (i.e.,
TRG 2–4 vs. 1), and found a sensitivity of 61 % and
specificity of 89 % [24]. These results led investigators to
examine the use of 18F-FDG PET to direct preoperative
therapy in patients with oesophageal cancer in the Cancer
and Leukemia Group B trial 80803, which was opened in
2011 [24]. Results of that trial, in which the chemotherapy
regimen to be used during preoperative CRT will be select-
ed by 18F-FDG PET response after induction chemotherapy,
are currently awaited.
Although 18F-FDG PET before and after induction
chemotherapy appears to have a reasonable discrimina-
tory ability for predicting pathologic response, it re-
mains suboptimal. Studies have been focusing mainly
on quantitative parameters, but subjective assessment
by clinicians is thought to have some additional poten-
tial, as it is felt that on post-treatment scans more fo-
cused 18F-FDG avidity instead of linear uptake may be
indicative of a poor response. Unfortunately, other mo-
dalities that have been extensively studied for predicting
pathologic response – including endoscopic biopsy, en-
doscopic ultrasonography, and CT – yielded unsatisfac-
tory results [38, 48]. Recently, diffusion-weighted mag-
netic resonance imaging has been suggested as poten-
tially powerful tool for this purpose [49], but this tool
Fig. 2 Kaplan-Meier analysis for progression-free survival (a) and
overall survival (b) according to predicted good versus poor response
by the change in the logarithmically transformed total lesion glycolysis
(ΔTLG) after induction chemotherapy before preoperative chemo-
radiotherapy for oesophageal cancer
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has not yet been described in the setting of a three-step
treatment strategy and requires further validation.
Besides pathologic response, 18F-FDG PET response
(ΔTLG) after induction chemotherapy was also significantly
associated with progression-free survival (p = 0.02) – but not
with overall survival (p = 0.18) – in the current study. This
finding is supported by a previous prospective study in which
18F-FDG PET responders to induction chemotherapy had sig-
nificantly improved progression-free survival (p = 0.02), but
not overall survival (p = 0.29) [24]. In this way, the early re-
sponse to induction chemotherapy apparently is an indicator
of tumour biology and the likelihood of treatment failure. As
such, the early 18F-FDG PET response after induction chemo-
therapy could aid in patient selection for treatment intensifi-
cation or modification aiming to reduce the high risk of
locoregional and distant recurrences in the poor responders.
Certain limitations apply to this study. First, the study was
retrospective by nature. Second, different regimens of induc-
tion chemotherapy and preoperative chemoradiotherapy were
applied in this study. However, our analysis was strengthened
by including the largest sample size for this topic so far, using
a prospectively maintained database, and using modern 18F-
FDG PET techniques and imaging analysis.
In conclusion, this study demonstrated that 18F-FDG PET
seems useful to predict a poor pathologic response early after
induction chemotherapy in patients with oesophageal adenocar-
cinoma undergoing a three-step treatment strategy. As such, the
early 18F-FDG PET response after induction chemotherapy has
the potential to aid in individualized treatment decision-making
in this group of patients. However, the standard use of 18F-FDG
PET for this indication cannot yet be recommended, as the find-
ings (e.g., the determined threshold) of the current exploratory
study require external validation. Also, a larger sample size is
desired as the 95 % CIs of the estimated diagnostic performance
indices in the current study were relatively wide. Also, additional
studies are required to determine and validate whether 18F-FDG
PETalone or in combination with other modalities provides suf-
ficient accuracy to justify modification or withdrawal of subse-
quent CRT prior to surgery.
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